News

Newsmogrifydigital2026-02-25T11:17:26+00:00

FEATURED

CONTENT

Mogrify extends Series A financing to $46 million USD

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

Latest

NEWS

Mogrify extends Series A financing to $46 million USD

Mark Cavanagh2025-08-20T14:48:33+00:002nd October 2023|

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mark Cavanagh2025-08-20T14:49:23+00:005th July 2022|

Mogrify completes Series A financing totaling $33 million USD

Mark Cavanagh2025-08-20T14:51:12+00:004th May 2021|

Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020

Mark Cavanagh2025-08-20T14:52:03+00:0026th March 2021|

Mogrify solidifies IP position surrounding core technology and expands platform algorithm to enhance cell conversion

Mark Cavanagh2022-05-09T10:42:22+00:0017th December 2020|

Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance

Mark Cavanagh2022-05-09T10:42:45+00:009th October 2020|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES